ReviewMedical microbiology and immunology2013
Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines.
Review in Medical microbiology and immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 70 citations in OpenAlex.
- Randomized, placebo-controlled phase II trial of heat-killed Mycobacterium vaccae (Longcom batch) formulated as an oral pill (V7).Human vaccines & immunotherapeutics · 2013Trial
- TAK1 phosphorylation mediates macozinone (PBTZ169) induced innate immune activation against tuberculosis.mSphere · 2025Article
- Enhanced Immune Responses AgainstIndian journal of microbiology · 2024Article
- Drug-resistant strains ofFrontiers in cellular and infection microbiology · 2023Review
- Targeted Anti-Biofilm Therapy: Dissecting Targets in the Biofilm Life Cycle.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Induction of autophagy through CLEC4E in combination with TLR4: an innovative strategy to restrict the survival ofAutophagy · 2020Article
- Historical BCG vaccination combined with drug treatment enhances inhibition of mycobacterial growth ex vivo in human peripheral blood cells.Scientific reports · 2019Observational
- Curdlan LimitsFrontiers in microbiology · 2019Article
- RUTI Vaccination Enhances Inhibition of Mycobacterial GrowthFrontiers in immunology · 2019Article
- The current status, challenges, and future developments of new tuberculosis vaccines.Human vaccines & immunotherapeutics · 2018Review
- A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis.PloS one · 2018Article
- Infergen Stimulated Macrophages Restrict Mycobacterium tuberculosis Growth by Autophagy and Release of Nitric Oxide.Scientific reports · 2016Article
- Drug-resistant TB: deadly, costly and in need of a vaccine.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2016Review
- Vaccination against infectious diseases: what is promising?Medical microbiology and immunology · 2014Review
- Use of an Sm-p80-based therapeutic vaccine to kill established adult schistosome parasites in chronically infected baboons.The Journal of infectious diseases · 2014Article
- Novel vaccination strategies against tuberculosis.Cold Spring Harbor perspectives in medicine · 2014Review
- Recent advances towards tuberculosis control: vaccines and biomarkers.Journal of internal medicine · 2014Review
- High-throughput identification and dendritic cell-based functional validation of MHC class I-restricted Mycobacterium tuberculosis epitopes.Scientific reports · 2014Article
- Immunotherapeutic efficacy of recombinant Mycobacterium smegmatis expressing Ag85B-ESAT6 fusion protein against persistent tuberculosis infection in mice.Human vaccines & immunotherapeutics · 2014Article
- Immunotherapy of tuberculosis with Mycobacterium leprae Hsp65 as a DNA vaccine triggers cross-reactive antibodies against mammalian Hsp60 but not pathological autoimmunity.Human vaccines & immunotherapeutics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 11 institutions in 13 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) has scourged humankind for millennia, and latent infection affects nearly one-third of today's world population. The emergence of multidrug-resistant (MDR)-TB is a major global threat and reflects treatment failure of drug-sensitive disease. MDR-TB management is a burden for patients and society; success rates are unacceptably low with prolonged treatment duration. Mycobacterium tuberculosis (Mtb) possesses the ability to transform into a dormant state in which it can persist in the face of antimicrobial treatment and host defense. This sub-population of persisters is largely responsible for lengthy and difficult treatment. Targeting persistent bacilli could eventually improve the treatment success rate (currently 50-65 %) and shorten duration of treatment. A subset of therapies in the pipeline, termed therapeutic vaccines, use the host immune response to attack Mtb. The historical occurrence of an exacerbated host response has resulted in a negative perception of therapeutic vaccines. Thus, a renewed concept of immunotherapy is needed. We review current perspectives of immunotherapy in MDR-TB based on the knowledge of TB immunology and briefly discuss the profiles of several therapeutic vaccine products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.